$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417040909 Filed on August 07, 2017

Income Statement

Concept	2017 Q2	2016 Q4	2016 Q2
Revenue	$1.867M	$2.587M	$1.552M
YoY Change	20.3%	33.14%	-26.58%
Cost Of Revenue	$1.471M	$1.740M	$1.349M
YoY Change	9.04%	-18.69%	-16.32%
Gross Profit	$396.0K	$843.0K	$203.0K
YoY Change	95.07%	-534.54%	-59.56%
Gross Profit Margin	21.21%	32.59%	13.08%
Selling, General & Admin	$5.745M	$5.430M	$5.378M
YoY Change	6.82%	22.85%	22.37%
% of Gross Profit	1450.76%	644.13%	2649.26%
Research & Development	$2.632M	$2.290M	$2.221M
YoY Change	18.51%	12.25%	27.5%
% of Gross Profit	664.65%	271.65%	1094.09%
Depreciation & Amortization	$400.0K	$480.0K	$470.0K
YoY Change	-14.89%	71.43%	113.64%
% of Gross Profit	101.01%	56.94%	231.53%
Operating Expenses	$8.855M	$7.530M	$7.599M
YoY Change	16.53%	16.56%	23.82%
Operating Profit	-$8.459M	-$6.687M	-$7.396M
YoY Change	14.37%	0.5%	31.25%
Interest Expense	$198.0K	$20.00K	-$34.00K
YoY Change	-682.35%		-1233.33%
% of Operating Profit
Other Income/Expense, Net	$2.952M	$1.090M	$1.631M
YoY Change	80.99%	-45.77%	-16410.0%
Pretax Income	-$5.510M	-$5.580M	-$5.770M
YoY Change	-4.51%	20.0%	2.12%
Income Tax
% Of Pretax Income
Net Earnings	-$5.507M	-$5.576M	-$5.765M
YoY Change	-4.48%	20.04%	2.13%
Net Earnings / Revenue	-294.97%	-215.54%	-371.46%
Basic Earnings Per Share		-$0.29	-$0.61
Diluted Earnings Per Share	-$3.241M	-$0.35	-$0.61
COMMON SHARES
Basic Shares Outstanding	25.63M shares	21.88M shares	16.18M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2016 Q4	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.70M	$16.85M	$4.660M
YoY Change	129.61%	-13.81%	-71.32%
Cash & Equivalents	$10.70M	$16.85M	$4.661M
Short-Term Investments
Other Short-Term Assets	$600.0K	$500.0K	$690.0K
YoY Change	-13.04%	-80.24%	-70.64%
Inventory	$1.896M	$1.556M	$2.410M
Prepaid Expenses
Receivables	$2.107M	$1.780M	$1.570M
Other Receivables	$0.00	$0.00	$40.00K
Total Short-Term Assets	$15.30M	$20.68M	$9.370M
YoY Change	63.3%	-17.92%	-57.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.562M	$2.435M	$2.580M
YoY Change	-0.7%	-7.24%	19.78%
Goodwill	$189.0K	$189.0K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$118.0K	$91.00K	$90.00K
YoY Change	31.11%	-6.19%	63.64%
Total Long-Term Assets	$3.631M	$3.741M	$4.210M
YoY Change	-13.75%	-46.53%	-10.88%
TOTAL ASSETS
Total Short-Term Assets	$15.30M	$20.68M	$9.370M
Total Long-Term Assets	$3.631M	$3.741M	$4.210M
Total Assets	$18.93M	$24.43M	$13.58M
YoY Change	39.41%	-24.14%	-49.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.068M	$2.374M	$2.070M
YoY Change	-0.1%	-11.88%	-10.23%
Accrued Expenses	$2.458M	$3.130M	$2.130M
YoY Change	15.4%	66.05%	7.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$972.0K	$50.00K	$80.00K
YoY Change	1115.0%	-37.5%	100.0%
Total Short-Term Liabilities	$6.587M	$6.314M	$5.790M
YoY Change	13.77%	-26.74%	-30.72%
LONG-TERM LIABILITIES
Long-Term Debt	$5.906M	$6.790M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$73.00K	$107.0K	$6.220M
YoY Change	-98.83%	-45.13%	36.4%
Total Long-Term Liabilities	$5.979M	$107.0K	$6.220M
YoY Change	-3.87%	-45.13%	34.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.587M	$6.314M	$5.790M
Total Long-Term Liabilities	$5.979M	$107.0K	$6.220M
Total Liabilities	$17.30M	$17.89M	$12.01M
YoY Change	44.08%	-23.5%	-7.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$128.8M	-$114.9M
YoY Change		25.68%
Common Stock	$26.00K	$22.00K	$16.00K
YoY Change	62.5%	46.67%	-84.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.628M	$6.531M	$1.560M
YoY Change
Total Liabilities & Shareholders Equity	$18.93M	$24.43M	$13.58M
YoY Change	39.41%	-24.14%	-49.53%

Cashflow Statement

Concept	2017 Q2	2016 Q4	2016 Q2
OPERATING ACTIVITIES
Net Income	-$5.507M	-$5.576M	-$5.765M
YoY Change	-4.48%	20.04%	2.13%
Depreciation, Depletion And Amortization	$400.0K	$480.0K	$470.0K
YoY Change	-14.89%	71.43%	113.64%
Cash From Operating Activities	-$9.610M	-$4.440M	-$7.330M
YoY Change	31.11%	-14.45%	58.32%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	-$370.0K	-$310.0K
YoY Change	-64.52%	-30.19%	10.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$110.0K	-$370.0K	-$310.0K
YoY Change	-64.52%	-30.19%	10.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.92M	8.770M	-10.00K
YoY Change	-109300.0%	-37.49%	-133.33%
NET CHANGE
Cash From Operating Activities	-9.610M	-4.440M	-7.330M
Cash From Investing Activities	-110.0K	-370.0K	-310.0K
Cash From Financing Activities	10.92M	8.770M	-10.00K
Net Change In Cash	1.200M	3.960M	-7.650M
YoY Change	-115.69%	-52.35%	56.76%
FREE CASH FLOW
Cash From Operating Activities	-$9.610M	-$4.440M	-$7.330M
Capital Expenditures	-$110.0K	-$370.0K	-$310.0K
Free Cash Flow	-$9.500M	-$4.070M	-$7.020M
YoY Change	35.33%	-12.66%	61.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2107000	USD
	us-gaap	Depreciation Depreciation	908000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1451000	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1867000	USD
CY2016Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	101000	USD
CY2017Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	0	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1552000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1867000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1286000	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1471000	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1471000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	203000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	396000	USD
CY2016Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2913000	USD
CY2017Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3270000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2221000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2632000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2465000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2475000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	7599000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8459000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1631000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2952000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-5765000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5507000	USD
CY2016Q2	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	4205000	USD
CY2017Q2	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5507000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9970000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	18000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9952000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-154000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-34000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9416000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13809000	USD
	us-gaap	Depreciation Depreciation	881000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1105000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-503000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	382000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1330000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	836000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	252000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-4590000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-620000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1257000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-7116000	USD
CY2016Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1026000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	189000	USD
CY2017Q2	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	762000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2458000	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	653000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	6531000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	217000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1556000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	1896000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16846000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10701000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	238000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-155000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	79000	USD
CY2017Q2	ekso	Business Combination Contingent Success Fee Liability BusinessCombinationContingentSuccessFeeLiability	37000	USD
CY2016Q4	ekso	Business Combination Contingent Success Fee Liability BusinessCombinationContingentSuccessFeeLiability	116000	USD
CY2017Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	5906000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	6789000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2068000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121291000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6587000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	805000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	91000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	22000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	73000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	17304000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	118000	USD
CY2017Q2	us-gaap	Assets Assets	18932000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	26000	USD
CY2016Q4	us-gaap	Assets Assets	24425000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	17894000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	130598000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2562000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6314000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	825000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	107000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1879000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128841000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114861000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	1628000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3556000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	948000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	20684000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24425000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	15301000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	502000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	597000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18932000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1780000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-203000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5710000	USD
CY2017Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1196000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1193000	USD
CY2017Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	106000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	198000	USD
CY2017Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	696000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	267000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	8855000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7396000	USD
CY2016Q2	us-gaap	Cost Of Services CostOfServices	63000	USD
CY2017Q2	us-gaap	Cost Of Services CostOfServices	0	USD
CY2016Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1349000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	122000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	328000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-851000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-29000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2139000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2333000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2333000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	440000	USD
CY2017Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7245000	USD
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	367000	USD
CY2017Q2	us-gaap	Long Term Debt LongTermDebt	6878000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14122000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2101000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-248000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14891000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6145000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19552000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4661000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16859000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	597000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	248000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-597000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	56000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	38000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-172000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10923000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	39000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	173000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	57000	USD
CY2017Q2	ekso	Unrestricted Cash And Cash Equivalents UnrestrictedCashAndCashEquivalents	3183000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	7518000	USD
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-234000	USD
CY2017Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	102000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	102000	USD
CY2017Q2	us-gaap	Deferred Revenue DeferredRevenue	1601000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	1630000	USD
CY2017Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	104000	USD
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	60000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	272000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	490000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1544000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2349000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	123000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	56000	USD
CY2017Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	123000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	203000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	275000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	110000	USD
CY2017Q2	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	338000	USD
CY2016Q4	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	483000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	355000	USD
CY2016Q4	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	686000	USD
	ekso	Product Maintenance Warranty Expense ProductMaintenanceWarrantyExpense	225000	USD
CY2017Q2	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	461000	USD
CY2017Q2	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	3000000	USD
	us-gaap	Accretion Expense AccretionExpense	48000	USD
CY2016Q4	ekso	Success Fee Expenses SuccessFeeExpenses	250000	USD
CY2016Q4	us-gaap	Share Price SharePrice	8.00
CY2016Q4	ekso	Contingent Success Fee Liability ContingentSuccessFeeLiability	37000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	972000	USD
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5906000	USD
CY2016Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	102000	USD
CY2017Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	108000	USD
CY2017Q2	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6935000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7629000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25789000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21894000	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25789000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21894000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	71429000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	71429000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25515000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16247000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14038000	USD
CY2017Q2	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	3106000	USD
CY2017Q2	us-gaap	Inventory Gross InventoryGross	1998000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	1658000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23717000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15817000	shares
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3275000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9508000	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	28000	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	530000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3303000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	10038000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2548000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7955000	USD
	us-gaap	Cost Of Services CostOfServices	7000	USD
	us-gaap	Cost Of Services CostOfServices	382000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2555000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8337000	USD
	us-gaap	Gross Profit GrossProfit	748000	USD
	us-gaap	Gross Profit GrossProfit	1701000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6337000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5416000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5505000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4370000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5016000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5953000	USD
	us-gaap	Operating Expenses OperatingExpenses	17348000	USD
	us-gaap	Operating Expenses OperatingExpenses	15739000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16600000	USD
CY2016Q2	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	1665000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	3037000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	4650000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-246000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-28000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2791000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4622000	USD
	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	USD
	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	7329000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13809000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16745000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-234000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	11000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14043000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16734000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1610000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	848000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	762000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3037000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4650000	USD
CY2017Q2	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0898	pure
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0888	pure
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	209000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	198000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3597000	shares
	ekso	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	1866000	shares
	ekso	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	371000	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5092000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0188	pure
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.78	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.78	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0128	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0143	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0188	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0229	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178	pure
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	527000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1105000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2101000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	709000	USD
CY2017Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	3810000	USD
CY2016Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	3546000	USD
CY2017Q2	us-gaap	Notes Payable Current NotesPayableCurrent	972000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2017Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	46000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	54000	USD
CY2017Q2	us-gaap	Restructuring Costs RestructuringCosts	665000	USD
CY2016Q2	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	665000	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	55000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	273000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-11000	USD
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	0	USD
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	90000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	95000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2017Q2	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	55000	USD
CY2016Q4	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	0	USD
CY2016Q4	ekso	Accrueds Restructuring Current AccruedsRestructuringCurrent	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	665000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	384000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	-186000	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	700000	USD
CY2017Q2	us-gaap	Severance Costs1 SeveranceCosts1	400000	USD
CY2017Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	200000	USD
CY2017Q2	ekso	Accrued Restructuring Current AccruedRestructuringCurrent	95000	USD
CY2016Q4	ekso	Accrued Restructuring Current AccruedRestructuringCurrent	0	USD
CY2017Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	27	pure
CY2017Q2	us-gaap	Other Restructuring Costs OtherRestructuringCosts	100000	USD
CY2017Q2	ekso	Accrueds Restructuring Current AccruedsRestructuringCurrent	95000	USD
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse
	ekso	Amortization Of Deferred Rent AmortizationOfDeferredRent	15000	USD
	ekso	Amortization Of Deferred Rent AmortizationOfDeferredRent	18000	USD
	us-gaap	Accretion Expense AccretionExpense	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	41000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	665000	USD
	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	58000	USD
	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	10919000	USD
	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Concentration of Credit Risk and Other Risks and Uncertainties</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.  We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of June 30, 2017 and December 31, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of June 30, 2017, we had one customer with an accounts receivable balance totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our total accounts receivable (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13</font>%) compared with three customers as of December 31, 2016 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>%).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In the three months ended June 30, 2017, we had two customers with revenue of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of total revenue (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>%), compared with two customers in the three months ended June 30, 2016 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>%). In the six months ended June 30, 2017, we had one customer with sales comprising <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our total customer sales (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14</font>%).We had no customers with sales 10% or more of total billed revenue in the six months ended June 30, 2016.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	187000	USD
CY2016Q2	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	0	USD
	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	175000	USD
	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	0	USD
	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	0	USD

Files In Submission

Name	View Source	Status
0001144204-17-040909-index-headers.html	Edgar Link	pending
0001144204-17-040909-index.html	Edgar Link	pending
0001144204-17-040909.txt	Edgar Link	pending
0001144204-17-040909-xbrl.zip	Edgar Link	pending
ekso-20170630.xml	Edgar Link	completed
ekso-20170630.xsd	Edgar Link	pending
ekso-20170630_cal.xml	Edgar Link	unprocessable
ekso-20170630_def.xml	Edgar Link	unprocessable
ekso-20170630_lab.xml	Edgar Link	unprocessable
ekso-20170630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v471408_10q.htm	Edgar Link	pending
v471408_ex10-46.htm	Edgar Link	pending
v471408_ex10-47.htm	Edgar Link	pending
v471408_ex10-48.htm	Edgar Link	pending
v471408_ex31-1.htm	Edgar Link	pending
v471408_ex31-2.htm	Edgar Link	pending
v471408_ex32-1.htm	Edgar Link	pending
v471408_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2017 Q2 Form 10-Q Financial Statement

#000114420417040909 Filed on August 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2017 Q2 Form 10-Q Financial Statement

#000114420417040909 Filed on August 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso